Literature DB >> 23121828

Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system.

Melissa F Natavio1, Deshawn Taylor, Radha A Lewis, Paul Blumenthal, Juan C Felix, Alexander Melamed, Elisabet Gentzschein, Frank Z Stanczyk, Daniel R Mishell.   

Abstract

BACKGROUND: The major contraceptive action of the levonorgestrel-releasing intrauterine system (LNG-IUS) is cervical mucus (CM) thickening, which prevents sperm penetration. No study to date has examined the temporal relationship between the insertion of the LNG-IUS and changes in CM quality and sperm penetration. STUDY
DESIGN: Participants were enrolled in a clinically descriptive study to compare the quality of CM and three parameters of sperm penetration prior to insertion of the LNG-IUS and on Days 1, 3 and 5 after insertion. Measurements of estradiol, progesterone and levonorgestrel (LNG) in serum and LNG in CM were also carried out at these times. CM was analyzed using the World Health Organization CM grading criteria. Sperm penetration was determined using an in vitro sperm-CM penetration test.
RESULTS: All 10 participants underwent LNG-IUS insertion during midcycle when CM quality was good and sperm penetration was excellent. On Day 1 after LNG-IUS insertion, the majority of participants demonstrated poor CM quality and poor sperm penetration. On Day 3, all participants had poor CM quality, and all but one subject had poor sperm penetration. By Day 5, all participants had poor CM quality and poor sperm penetration. LNG levels in CM peaked on the day after LNG-IUS insertion.
CONCLUSION: Significant changes in quality of CM and sperm penetration were observed shortly after LNG-IUS insertion; however, CM can remain penetrable for up to 5 days when the LNG-IUS is inserted midcycle.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23121828     DOI: 10.1016/j.contraception.2012.09.034

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

1.  The levonorgestrel-releasing intrauterine system is associated with delayed endocervical clearance of Chlamydia trachomatis without alterations in vaginal microbiota.

Authors:  Emma R Liechty; Ingrid L Bergin; Christine M Bassis; Daniel Chai; William LeBar; Vincent B Young; Jason D Bell
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

2.  Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.

Authors:  Andrea R Thurman; Vivian Brache; Leila Cochon; Louise A Ouattara; Neelima Chandra; Terry Jacot; Nazita Yousefieh; Meredith R Clark; Melissa Peet; Homaira Hanif; Jill L Schwartz; Susan Ju; Mark A Marzinke; David W Erikson; Urvi Parikh; Betsy C Herold; Raina N Fichorova; Elizabeth Tolley; Gustavo F Doncel
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

Review 3.  Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Jennifer A Hurlburt; Gustavo F Doncel
Journal:  Int J Womens Health       Date:  2013-10-21

4.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

5.  Rates of pregnancy among levonorgestrel and copper intrauterine emergency contraception initiators: Implications for backup contraception recommendations.

Authors:  Kathryn E Fay; Amelia C Clement; Alexandra Gero; Jennifer E Kaiser; Jessica N Sanders; Abena A BakenRa; David K Turok
Journal:  Contraception       Date:  2021-06-21       Impact factor: 3.051

Review 6.  Bridging progestogens in pregnancy and pregnancy prevention.

Authors:  Elizabeth Micks; Greta B Raglan; Jay Schulkin
Journal:  Endocr Connect       Date:  2015-12       Impact factor: 3.335

Review 7.  New developments in intrauterine device use: focus on the US.

Authors:  Anita L Nelson; Natasha Massoudi
Journal:  Open Access J Contracept       Date:  2016-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.